Revance Therapeutics Company Profile (NASDAQ:RVNC)

About Revance Therapeutics

Revance Therapeutics logoRevance Therapeutics, Inc. is a biotechnology company. The Company is focused on the development, manufacturing and commercialization of botulinum toxin products for multiple aesthetic and therapeutic indications. Its TransMTS technology enables delivery of botulinum toxin type A through investigational drug product candidates, including DaxibotulinumtoxinA Topical Gel (RT001), or RT001 topical, and DaxibotulinumtoxinA for Injection (RT002), or RT002 injectable. Its botulinum toxin-peptide complex has over two components that contribute to the performance of RT001 and RT002. Its TransMTS peptide provides the delivery across the skin and restricts the toxin molecule to the target site. Then, the botulinum toxin type A provides the mechanism of pharmacologic action and is responsible for the drug effects demonstrated in its clinical trials. Its TransMTS peptide technology serves various purposes depending on whether it is used in a topical formulation or in an injectable formulation.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Biotechnology
  • Sub-Industry: N/A
  • Exchange: NASDAQ
  • Symbol: RVNC
  • CUSIP:
Key Metrics:
  • Previous Close: $20.40
  • 50 Day Moving Average: $21.05
  • 200 Day Moving Average: $17.43
  • 52-Week Range: $12.35 - $24.30
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -5.98
  • P/E Growth: -0.58
  • Market Cap: $567.45M
  • Outstanding Shares: 28,515,000
  • Beta: 1.7
Profitability:
  • Net Margins: -28,187.33%
  • Return on Equity: -37.31%
  • Return on Assets: -33.87%
Debt:
  • Debt-to-Equity Ratio: 0.01%
  • Current Ratio: 11.92%
  • Quick Ratio: 11.92%
Additional Links:
Companies Related to Revance Therapeutics:

Analyst Ratings

Consensus Ratings for Revance Therapeutics (NASDAQ:RVNC) (?)
Ratings Breakdown: 1 Hold Rating, 4 Buy Ratings
Consensus Rating:Buy (Score: 2.80)
Consensus Price Target: $37.60 (88.94% upside)

Analysts' Ratings History for Revance Therapeutics (NASDAQ:RVNC)
Show:
DateFirmActionRatingPrice TargetDetails
1/19/2017AegisReiterated RatingBuy$28.00View Rating Details
8/5/2016Brean CapitalReiterated RatingHoldView Rating Details
6/14/2016SunTrust Banks, Inc.Lower Price TargetBuy$46.00 -> $22.00View Rating Details
6/14/2016Piper Jaffray CompaniesReiterated RatingOverweight$54.00 -> $35.00View Rating Details
6/14/2016GuggenheimReiterated RatingBuy$55.00View Rating Details
12/30/2015Cowen and CompanyReiterated RatingBuyView Rating Details
11/10/2015William BlairReiterated RatingBuy$59.00View Rating Details
6/6/2015BMO Capital MarketsReiterated RatingOutperform$24.00 -> $35.00View Rating Details
(Data available from 2/24/2015 forward)

Earnings

Earnings History for Revance Therapeutics (NASDAQ:RVNC)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
2/27/2017Q416($0.84)N/AView Earnings Details
11/3/2016Q316($0.89)($0.64)$70.00 millionViewN/AView Earnings Details
8/4/2016Q216($0.86)($0.88)$0.06 million$0.80 millionViewN/AView Earnings Details
5/9/2016Q1($0.83)($0.71)$0.08 millionViewListenView Earnings Details
3/2/2016Q415($0.86)($0.83)$0.09 million$0.08 millionViewListenView Earnings Details
11/9/2015Q315($1.01)($0.81)$0.10 million$0.08 millionViewN/AView Earnings Details
8/6/2015Q415($0.84)($0.71)ViewN/AView Earnings Details
5/13/2015Q1($0.69)($0.65)ViewListenView Earnings Details
3/2/2015($0.53)($0.60)ViewN/AView Earnings Details
11/12/2014Q314($0.69)($0.60)ViewN/AView Earnings Details
8/12/2014($0.68)($0.69)ViewN/AView Earnings Details
5/13/2014Q1 14($0.87)($1.93)ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Revance Therapeutics (NASDAQ:RVNC)
Current Year EPS Consensus Estimate: $-3.17 EPS
Next Year EPS Consensus Estimate: $-3.33 EPS
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20162($1.07)($0.66)($0.87)
Q2 20162($0.91)($0.91)($0.91)
Q3 20162($0.95)($0.93)($0.94)
Q4 20162($1.02)($0.95)($0.99)
(Data provided by Zacks Investment Research)

Dividends

Dividend History for Revance Therapeutics (NASDAQ:RVNC)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading History for Revance Therapeutics (NASDAQ:RVNC)
Insider Ownership Percentage: 31.15%
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
1/25/2017L Daniel BrowneCEOSell12,000$19.78$237,360.00View SEC Filing  
12/28/2016L Daniel BrowneCEOSell12,000$20.94$251,280.00View SEC Filing  
11/25/2016L Daniel BrowneCEOSell12,000$17.92$215,040.00View SEC Filing  
10/26/2016L Daniel BrowneCEOSell12,000$14.85$178,200.00View SEC Filing  
6/13/2016Curtis RueggEVPSell1,000$18.25$18,250.00View SEC Filing  
5/9/2016Curtis RueggEVPSell1,000$16.18$16,180.00View SEC Filing  
4/11/2016Curtis RueggEVPSell1,000$19.11$19,110.00View SEC Filing  
3/7/2016Curtis RueggEVPSell1,000$20.43$20,430.00View SEC Filing  
2/8/2016Curtis RueggEVPSell1,000$18.14$18,140.00View SEC Filing  
1/6/2016Curtis RueggEVPSell2,000$33.06$66,120.00View SEC Filing  
11/17/2015Arthur Peter BertolinoEVPSell7,753$39.11$303,219.83View SEC Filing  
8/17/2015Curtis RueggEVPSell3,000$30.33$90,990.00View SEC Filing  
7/17/2015Curtis RueggEVPSell3,000$31.03$93,090.00View SEC Filing  
6/17/2015Curtis RueggEVPSell3,000$33.53$100,590.00View SEC Filing  
5/18/2015Curtis RueggEVPSell3,000$26.42$79,260.00View SEC Filing  
4/17/2015Curtis RueggEVPSell2,000$22.23$44,460.00View SEC Filing  
3/17/2015Curtis RueggEVPSell1,500$18.61$27,915.00View SEC Filing  
3/9/2015Curtis RueggEVPSell500$18.00$9,000.00View SEC Filing  
2/17/2015Curtis RueggEVPSell1,000$16.80$16,800.00View SEC Filing  
1/20/2015Curtis RueggEVPSell1,000$17.25$17,250.00View SEC Filing  
12/17/2014Curtis RueggEVPSell1,000$16.45$16,450.00View SEC Filing  
11/28/2014L Daniel BrowneCEOBuy6,000$16.67$100,020.00View SEC Filing  
11/18/2014Curtis RueggEVPSell1,000$16.00$16,000.00View SEC Filing  
9/17/2014Curtis RueggEVPSell2,000$20.55$41,100.00View SEC Filing  
9/17/2014Jacob WaughInsiderSell97,713$20.73$2,025,590.49View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Latest Headlines for Revance Therapeutics (NASDAQ:RVNC)
DateHeadline
News IconStock Spotlight: Zooming in on Shares of Revance Therapeutics, Inc. (NASDAQ:RVNC) - BVN (NASDAQ:RVNC)
bvnewsjournal.com - February 22 at 7:49 PM
finance.yahoo.com logoRevance to Participate in Upcoming Investor Conferences (NASDAQ:RVNC)
finance.yahoo.com - February 22 at 7:49 PM
finance.yahoo.com logoRevance Therapeutics to Release Fourth Quarter 2016 Financial Results Monday, February 27, 2017 (NASDAQ:RVNC)
finance.yahoo.com - February 16 at 7:18 PM
News IconInvestor Radar: Taking a Closer Look at Revance Therapeutics, Inc. (NASDAQ:RVNC) - Piedmont Register (NASDAQ:RVNC)
piedmontregister.com - February 15 at 1:31 AM
biz.yahoo.com logoREVANCE THERAPEUTICS, INC. Files SEC form 8-K, Change in Directors or Principal Officers (NASDAQ:RVNC)
biz.yahoo.com - February 8 at 11:44 PM
capitalcube.com logoRevance Therapeutics, Inc. breached its 50 day moving average in a Bearish Manner : RVNC-US : January 31, 2017 (NASDAQ:RVNC)
www.capitalcube.com - January 31 at 10:12 PM
4-traders.com logoRevance Therapeutics : BELMONT Phase 2 Clinical Data to be Presented at IMCAS World Congress 2017 (NASDAQ:RVNC)
www.4-traders.com - January 27 at 2:34 AM
uk.finance.yahoo.com logoBELMONT Phase 2 Clinical Data to be Presented at IMCAS World Congress 2017 (NASDAQ:RVNC)
us.rd.yahoo.com - January 27 at 2:34 AM
News IconGrowth Story Unfolding for Revance Therapeutics, Inc. (NASDAQ:RVNC) - Prospect Journal (NASDAQ:RVNC)
prospectjournal.com - January 24 at 12:59 AM
News IconEarnings Analysis & Update for Revance Therapeutics, Inc. (NASDAQ:RVNC)? - Aiken Advocate (NASDAQ:RVNC)
aikenadvocate.com - January 24 at 12:59 AM
News IconRevance Therapeutics Inc RVNC Pharmaceuticals Healthcare Deals and Alliances Profile Prices from USD $250 (NASDAQ:RVNC)
www.bioportfolio.com - January 23 at 12:23 AM
4-traders.com logoRevance Therapeutics : Presents Clinical Data for RT002 Injectable at TOXINS 2017 (NASDAQ:RVNC)
www.4-traders.com - January 18 at 9:03 PM
us.rd.yahoo.com logoRevance Presents Clinical Data for RT002 Injectable at TOXINS 2017 (NASDAQ:RVNC)
us.rd.yahoo.com - January 18 at 9:03 PM
News IconInvestors Priming the Pump as Stock Reaches Most Volatile List: Revance Therapeutics, Inc. (NASDAQ:RVNC) - Wall Street Beacon (NASDAQ:RVNC)
wsbeacon.com - January 17 at 8:02 PM
biz.yahoo.com logoREVANCE THERAPEUTICS, INC. Files SEC form 8-K, Other Events (NASDAQ:RVNC)
biz.yahoo.com - January 12 at 9:01 PM
marketexclusive.com logoREVANCE THERAPEUTICS, INC. (NASDAQ:RVNC) Files An 8-K Results of Operations and Financial Condition - Market Exclusive (NASDAQ:RVNC)
marketexclusive.com - January 9 at 9:04 PM
streetinsider.com logoRevance Therapeutics (RVNC) Offers FY17 Outlook - StreetInsider.com (NASDAQ:RVNC)
www.streetinsider.com - January 8 at 12:20 AM
streetinsider.com logoRevance Therapeutics (RVNC) Offers FY17 Outlook (NASDAQ:RVNC)
www.streetinsider.com - January 6 at 3:23 AM
us.rd.yahoo.com logoRevance Provides Clinical Milestones and Financial Outlook for 2017 (NASDAQ:RVNC)
us.rd.yahoo.com - January 6 at 3:23 AM
us.rd.yahoo.com logo4:18 pm Revance Therapeutics expects cash burn for 2017 to be in the range of $102 to $112 mln; provides clinical updates (NASDAQ:RVNC)
us.rd.yahoo.com - January 6 at 3:23 AM
biz.yahoo.com logoREVANCE THERAPEUTICS, INC. Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements an (NASDAQ:RVNC)
biz.yahoo.com - January 6 at 3:23 AM
News IconUpside Alert: Delving into Shares of Revance Therapeutics, Inc. (NASDAQ:RVNC) - Prospect Journal (NASDAQ:RVNC)
prospectjournal.com - December 26 at 6:53 PM
News IconWhat The Charts Are Saying About Revance Therapeutics, Inc. (NASDAQ:RVNC) - The Business Journal (NASDAQ:RVNC)
belmontbusinessjournal.com - December 18 at 1:19 AM
capitalcube.com logoRevance Therapeutics, Inc. – Value Analysis (NASDAQ:RVNC) : December 15, 2016 (NASDAQ:RVNC)
www.capitalcube.com - December 16 at 2:47 AM
News IconValue Composite Score Update on Revance Therapeutics, Inc. (NASDAQ:RVNC) - Marion Business Daily (NASDAQ:RVNC)
marionbusinessdaily.com - December 14 at 9:54 PM
capitalcube.com logoRevance Therapeutics, Inc. breached its 50 day moving average in a Bullish Manner : RVNC-US : December 14, 2016 (NASDAQ:RVNC)
www.capitalcube.com - December 14 at 9:54 PM
4-traders.com logoRevance Therapeutics : NetworkNewsBreaks – Revance Therapeutics, Inc. (RVNC) Reports Positive Preliminary from Phase 2 Cervical Dystonia Trial (NASDAQ:RVNC)
www.4-traders.com - December 13 at 8:02 PM
News IconTrading Activity in Focus for Revance Therapeutics Inc. (RVNC) - StockTalk Daily (NASDAQ:RVNC)
stocktalkdaily.com - December 13 at 12:47 AM
finance.yahoo.com logoRevance Announces Positive 24-Week Duration of Effect in Interim Results from Phase 2 Cervical Dystonia Trial (NASDAQ:RVNC)
finance.yahoo.com - December 12 at 7:44 PM
finance.yahoo.com logo4:06 pm Revance Therapeutics announces positive interim results from its U.S. Phase 2 open-label, dose-escalating clinical study of DaxibotulinumtoxinA Injectable (RT002) to treat moderate-to-severe isolated cervical dystonia in adults (NASDAQ:RVNC)
finance.yahoo.com - December 12 at 7:44 PM
biz.yahoo.com logoREVANCE THERAPEUTICS, INC. Files SEC form 8-K, Regulation FD Disclosure, Other Events, Financial Statements and Exhib (NASDAQ:RVNC)
biz.yahoo.com - December 12 at 7:44 PM
seekingalpha.com logoDosing commences in Revance's late-stage studies of RT002 for frown lines (NASDAQ:RVNC)
seekingalpha.com - December 8 at 8:03 PM
News IconRevance Therapeutics, Inc. (RVNC) is “One to Watch” (NASDAQ:RVNC)
missionir.com - December 8 at 8:03 PM
finance.yahoo.com logoRevance Announces Initiation of Subject Dosing in the SAKURA Phase 3 Clinical Program of RT002 Injectable for the Treatment of Glabellar (Frown) Lines (NASDAQ:RVNC)
finance.yahoo.com - December 7 at 8:50 AM
News IconFollowing FCF Scores for Revance Therapeutics, Inc. (NASDAQ:RVNC) - The Business Journal (NASDAQ:RVNC)
belmontbusinessjournal.com - December 6 at 7:17 PM
News IconTop Stock With Upside & Growth Potential: Revance Therapeutics, Inc. (NASDAQ:RVNC) - Prospect Journal (NASDAQ:RVNC)
prospectjournal.com - December 6 at 8:50 AM
investornewswire.com logoRevance Therapeutics, Inc. (NASDAQ:RVNC) EPS Estimate At $-0.89 - Investor Newswire (NASDAQ:RVNC)
www.investornewswire.com - December 4 at 6:35 PM
News IconStock Update: Focusing on Shares of Revance Therapeutics, Inc. (NASDAQ:RVNC) - The Business Journal (NASDAQ:RVNC)
belmontbusinessjournal.com - December 3 at 6:41 PM
News IconFCF Score Check on Shares of Revance Therapeutics, Inc. (NASDAQ:RVNC) - Marion Business Daily (NASDAQ:RVNC)
marionbusinessdaily.com - December 3 at 10:20 AM
capitalcube.com logoETFs with exposure to Revance Therapeutics, Inc. : December 2, 2016 (NASDAQ:RVNC)
www.capitalcube.com - December 2 at 7:13 PM
News IconFree Cash Flow Score in Focus for Revance Therapeutics, Inc. (NASDAQ:RVNC) - The Business Journal (NASDAQ:RVNC)
belmontbusinessjournal.com - December 1 at 8:09 AM
finance.yahoo.com logoCoverage initiated on Revance Therapeutics by Aegis Capital (NASDAQ:RVNC)
finance.yahoo.com - November 29 at 3:10 PM
News IconWhat Are the Numbers Saying About: Revance Therapeutics, Inc. (NASDAQ:RVNC) - The Business Journal (NASDAQ:RVNC)
belmontbusinessjournal.com - November 28 at 3:15 PM
News IconTechnical Buzz on Revance Therapeutics, Inc. (NASDAQ:RVNC) - The Business Journal (NASDAQ:RVNC)
belmontbusinessjournal.com - November 27 at 8:16 AM
News IconWhat are the Technical Charts Saying About Revance Therapeutics Inc. (RVNC) - StockTalk Daily (NASDAQ:RVNC)
stocktalkdaily.com - November 24 at 10:37 AM
News IconInvestor Focus: Watching Shares of Revance Therapeutics, Inc. (NASDAQ:RVNC) - Marion Business Daily (NASDAQ:RVNC)
marionbusinessdaily.com - November 19 at 9:51 AM
News IconRevance Therapeutics, Inc. RVNC Financial and Strategic SWOT Analysis Review Prices from USD $300 (NASDAQ:RVNC)
www.bioportfolio.com - November 18 at 10:34 AM
finance.yahoo.com logoRevance to Participate in the 28th Annual Piper Jaffray Healthcare Conference (NASDAQ:RVNC)
finance.yahoo.com - November 17 at 6:57 PM
News IconShares in Focus: Revance Therapeutics, Inc. (NASDAQ:RVNC) - The Business Journal (NASDAQ:RVNC)
belmontbusinessjournal.com - November 16 at 7:34 PM
capitalcube.com logoRevance Therapeutics, Inc. breached its 50 day moving average in a Bullish Manner : RVNC-US : November 10, 2016 (NASDAQ:RVNC)
www.capitalcube.com - November 10 at 10:30 AM

Social

What is Revance Therapeutics' stock symbol?

Revance Therapeutics trades on the NASDAQ under the ticker symbol "RVNC."

Where is Revance Therapeutics' stock going? Where will Revance Therapeutics' stock price be in 2017?

5 analysts have issued 1-year price targets for Revance Therapeutics' stock. Their predictions range from $22.00 to $55.00. On average, they anticipate Revance Therapeutics' stock price to reach $37.60 in the next twelve months.

When will Revance Therapeutics announce their earnings?

Revance Therapeutics is scheduled to release their next quarterly earnings announcement on Tuesday, February, 28th 2017.

What are analysts saying about Revance Therapeutics stock?

Here are some recent quotes from research analysts about Revance Therapeutics stock:

  • According to Zacks Investment Research, "Revance is a Silicon Valley-based biotechnology company. The company is developing a portfolio of products for aesthetic medicine and underserved therapeutic specialties, including dermatology and neurology. Revance's science is based upon a proprietary TransMTS® peptide technology, which when combined with active drug molecules, may help address current unmet needs. Revance's initial focus is on developing daxibotulinumtoxinA, the company's highly purified botulinum toxin, for a broad spectrum of aesthetic and therapeutic indications, including facial wrinkles and muscle movement disorders. The company's lead drug candidate, DaxibotulinumtoxinA for Injection (RT002), is currently in development for the treatment of glabellar lines and cervical dystonia and has the potential to be the first long-acting neurotoxin. The company holds worldwide rights for all indications of RT002 injectable and RT001 topical and the pharmaceutical uses of the TransMTS technology platform. " (1/12/2017)

  • Brean Capital analysts commented, "more clarity on the Phase III trial design for Glabellar lines" before rating the company as a Buy. Taking into consideration RT-001's loss and Glabellar lines' lack of visibility, the analyst claimed there were "no meaningful catalysts in the immediate time horizon." (6/14/2016)

Who owns Revance Therapeutics stock?

Revance Therapeutics' stock is owned by a number of of institutional and retail investors. Top institutional investors include Franklin Resources Inc. (11.50%), Arrowpoint Asset Management LLC (7.08%), State Street Corp (1.14%), FMR LLC (0.35%), Vivo Capital LLC (0.27%) and Federated Investors Inc. PA (0.07%). Company insiders that own Revance Therapeutics stock include Arthur Peter Bertolino, Curtis Ruegg and L Daniel Browne.

Who bought Revance Therapeutics stock? Who is buying Revance Therapeutics stock?

Revance Therapeutics' stock was bought by a variety of institutional investors in the last quarter, including Arrowpoint Asset Management LLC, Franklin Resources Inc., FMR LLC, State Street Corp and Russell Investments Group Ltd..

How do I buy Revance Therapeutics stock?

Shares of Revance Therapeutics can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

How much does a share of Revance Therapeutics stock cost?

One share of Revance Therapeutics stock can currently be purchased for approximately $19.90.

Revance Therapeutics (NASDAQ:RVNC) Chart for Friday, February, 24, 2017


Institutional Ownership Chart

Institutional Ownership by Quarter for Revance Therapeutics (NASDAQ:RVNC)

Earnings History Chart

Earnings by Quarter for Revance Therapeutics (NASDAQ:RVNC)

Dividend History Chart

Dividend Payments by Quarter for Revance Therapeutics (NASDAQ:RVNC)

Last Updated on 2/24/2017 by MarketBeat.com Staff